- Home
- OCGN
OCGN
Ocugen Inc.
as 07-26-2024 4:00pm EST
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 342.3M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 6.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $2.10 | Next Earning Date: | 08-19-2024 |
| Revenue: | $7,050,000 | Revenue Growth: | 140.53% |
| Revenue Growth (this year): | -82.99% | Revenue Growth (next year): | N/A |
Latest Ocugen Inc. News
OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Motley Fool
15 days ago
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
Zacks
a month ago
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
MT Newswires
a month ago
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
GlobeNewswire
a month ago
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
GlobeNewswire
a month ago
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
Compare OCGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCGN Ocugen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.